Treatment of chronic hepatitis C among injecting drug users: A 5-year follow-up

Ruzic, Maja; Fabri, Milotka; Preveden, Tomislav; Kiralj, Katarina; Mikić, Sandra Stefan; Vukadinov, Tatjana

doi:10.2298/vsp110311050r

VOJNOSANIT PREGL

2013

DOI: 10.2298/vsp110311050r

|View full text |Cite

Treatment of chronic hepatitis C among injecting drug users: A 5-year follow-up

Maja Ruzic

Milotka Fabri

Tomislav Preveden

et al.

Abstract: In a 5-year follow-up period 73.3% of the patients used to come regularly to check-ups and among them neither the opiate abuse recurrence nor HCV infection recurrence were registered.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2018

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

Martinello¹,

Hajarizadeh²,

Grebely³

et al. 2017

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Concern that HCV reinfection may compromise HCV treatment outcomes is sometimes cited as a reason for not offering treatment to current and former PWID. However, the incidence of reinfection following interferon-based treatment for chronic HCV is low among PWID. Reinfection rates in HIV-positive men-who-have-sex-with-men (MSM) are varied, with high incidence reported in some cohorts. Mathematical modelling suggests that substantial reductions in HCV incidence and prevalence could be achieved with targeted DAA therapy among those at the highest risk of ongoing transmission. This review will summarise the recent literature on DAA efficacy in PWID and people with HIV/HCV coinfection, discuss the individual- and population-level impact of DAA treatment scale-up and reinfection, and highlight ongoing and future research questions in expanding HCV care and treatment to those populations at high risk of ongoing HCV transmission.

show abstract

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

Martinello¹,

Hajarizadeh²,

Grebely³

et al. 2017

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

show abstract

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs

Martinello

Dore

Matthews

et al. 2018

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of chronic hepatitis C among injecting drug users: A 5-year follow-up

Abstract: In a 5-year follow-up period 73.3% of the patients used to come regularly to check-ups and among them neither the opiate abuse recurrence nor HCV infection recurrence were registered.

Cited by 2 publications

References 13 publications

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs

Contact Info

Product

Resources

About